» Articles » PMID: 31778805

Identifying Patients With Inflammatory Bowel Diseases At High Vs Low Risk of Complications

Overview
Specialty Gastroenterology
Date 2019 Nov 29
PMID 31778805
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

People with Crohn's disease and ulcerative colitis have varying presentations and clinical consequences of their disease. Patients commonly ask about their prognosis, and what this diagnosis means for them. They are asking their clinicians to predict the future. The importance of predicting the course of any disease is to guide patient expectations and to guide treatment decisions. In the past decade the strategy of inflammatory bowel disease (IBD) treatment has shifted to treat patients earlier in the course of their disease, before irreversible damage occurs. Treatment approaches for disease categorized as mild, moderate or severe has most often been based on a current assessment of symptoms or disease activity without including a longitudinal assessment of a patient's disease course including past disease complications and surgeries. While a patient's current disease activity most typically drives these treatment decisions, optimally, treatment decisions would be made accounting for past disease activity and complications and the predicted future disease course. When developing a treatment plan for an individual patient, the immediate goal is to treat the current disease activity for relief of symptoms, and the long-term goal is to prevent progression of their disease due to complications. Since not all patients will progress to a complicated disease course, it is important to be able to select the right patients for the right therapy. Therefore, developing methods of stratifying patients into low-risk versus high-risk of complications will be an important aspect of treating IBD now and in the future.

Citing Articles

What is first-line and what is second-line therapy in adult patients with moderate to severe Crohn's disease?.

Panaccione R J Can Assoc Gastroenterol. 2025; 8(Suppl 2):S1-S5.

PMID: 39990514 PMC: 11842895. DOI: 10.1093/jcag/gwae053.


Crohn's disease management: translating STRIDE-II for UK clinical practice.

Kemp K, Samaan M, Verma A, Lobo A Therap Adv Gastroenterol. 2024; 17:17562848241280885.

PMID: 39526077 PMC: 11544685. DOI: 10.1177/17562848241280885.


Ten-year outcomes of a prospective population-based incidence cohort of inflammatory bowel disease patients from Canterbury, New Zealand.

Forbes A, Frampton C, Day A, DeVries M, McVicar N, Su H JGH Open. 2024; 8(10):e70038.

PMID: 39403112 PMC: 11472240. DOI: 10.1002/jgh3.70038.


Exploration and verification a 13-gene diagnostic framework for ulcerative colitis across multiple platforms via machine learning algorithms.

Wang J, Li L, Chen P, He C, Niu X Sci Rep. 2024; 14(1):15009.

PMID: 38951638 PMC: 11217275. DOI: 10.1038/s41598-024-65481-8.


Summary of the best evidence on self-management support schemes for patients with inflammatory bowel disease based on mobile health systems.

Ren C, Zhou Y, Cai Q, Zhou M Digit Health. 2024; 10:20552076241261906.

PMID: 38868366 PMC: 11168054. DOI: 10.1177/20552076241261906.